Lipocine Inc
LPCN3.200USD
+0.050+1.59%
取引時間 （ET）15分遅れの株価
17.12M時価総額
損失額直近12ヶ月PER
詳細情報 Lipocine Inc 企業名
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
企業情報
企業コードLPCN
会社名Lipocine Inc
上場日Mar 21, 2014
最高経営責任者「CEO」Dr. Mahesh V. Patel, Ph.D.
従業員数16
証券種類Ordinary Share
決算期末Mar 21
本社所在地675 S Arapeen Dr Ste 202
都市SALT LAKE CITY
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号84108-1295
電話番号18019947383
ウェブサイトhttps://www.lipocine.com/
企業コードLPCN
上場日Mar 21, 2014
最高経営責任者「CEO」Dr. Mahesh V. Patel, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
株主統計
株主統計
比率
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
種類
株主統計
比率
Investment Advisor
6.79%
Individual Investor
2.95%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.72%
Research Firm
0.05%
Other
87.32%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
44
678.23K
12.68%
-42.35K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
2023Q1
97
745.08K
14.31%
-142.00K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
226.28K
4.23%
+4.82K
+2.18%
Mar 31, 2025
Patel (Mahesh V)
109.05K
2.04%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.67%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
58.83K
1.1%
+1.37K
+2.38%
Mar 31, 2025
Higuchi (John W)
40.80K
0.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
38.98K
0.73%
+13.97K
+55.89%
Mar 31, 2025
Renaissance Technologies LLC
37.51K
0.7%
+1.48K
+4.10%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
24.93K
0.47%
+4.42K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
18.63K
0.35%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
13.16K
0.25%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
日付
種類
比率
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
